Bank of America Securities: Reiterates "Buy" rating on ALI HEALTH (00241) with target price raised to 5.2 Hong Kong dollars.

Bank of America Securities released a research report stating that it is expected that ALI HEALTH (00241) will see a 10% year-on-year growth in revenue from the end of September last year to the first half of the 2025 fiscal year, accelerating to a 15% year-on-year growth from the end of March this year to the second half of the 2025 fiscal year, which is close to JD HEALTH (06618) with a growth forecast of 16%. Bank of America Securities has raised ALI HEALTH's target price from HK$4.6 to HK$5.2 and reiterated a "buy" rating. The bank stated that it maintains its performance forecast for ALI HEALTH up to the end of the 2025 fiscal year, which is higher than market consensus and company guidance. Specifically, revenue is expected to grow by 13% year-on-year, higher than market forecasts and company guidance of 12% and over 10%, respectively; adjusted net profit is expected to grow by 46% year-on-year, compared to market consensus and company guidance of 1.95 billion and over 2 billion yuan, respectively.